Biopharma Cred. Regulatory News (BPCR)

19 June 2026

BIOPHARMA CREDIT PLC 

("BIOPHARMA CREDIT" OR THE "COMPANY") 

DIVIDEND DECLARATION

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, is pleased to declare an interim dividend in respect of the quarterly financial period ending 30 June 2026 of 1.75 cents per share, payable on 31 July 2026 to ordinary shareholders on the register as at 3 July 2026. The ex-dividend date will be 2 July 2026.

The Company aims to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from its investments in the life sciences industry. The Company currently pays, and continues to target, a 7-cent base annual dividend per ordinary share in four quarterly payments of 1.75 cents per share. Typically, these are supplemented by excess income in the form of special dividend distributions in Q4 and in some years, Q3 and Q4, where the Board determines that it is appropriate and able to do so (noting the requirement to pay out substantially all income to maintain the Company's investment trust status).

Dividends in recent years:

By way of reference, the Company's shares traded as of (18 June 2026) at a price of 95.40 cents.

The default payment for dividends is in US dollars. However, shareholders can elect to have dividends paid in sterling (GBP) and the option to elect a sterling dividend payment for this dividend will be available to shareholders until 3 July 2026 (being the "Election Date").

The Company has chosen to designate the entire amount of this interim dividend as an interest distribution. Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest. This will result in a reduction in the corporation tax payable by the Company.

A copy of the Dividend Currency Election Form, which should be sent to MUFG Corporate Markets, Central Square, 29 Wellington St, Leeds LS1 4DL when completed, will be available on the Company's website at www.bpcruk.com/investor-materials. CREST shareholders must elect via CREST.

Enquiries:

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

Burson Buchanan

Henry Wilson / Helen Tarbet / Jamie Hooper / Nick Croysdill

+44 (0) 20 7466 5000

biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24